Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago. These figures are ...

From the intensifying battle over weight-loss drugs to the rise of AI to the uncertainty about President-elect Donald Trump's second term, biotech stocks won't be boring in 2025. Biotech may even ...